Biocon Stock Drops 6% After Biosimilar Unit Investment Announcement

Biocon shares fell 6% after the company announced plans to invest in its biosimilar unit. The investment decision raised concerns among investors about the potential financial impact and the company's ability to manage its expenses. The market reacted negatively, causing the stock to decline. The firm's focus on expanding its biosimilar portfolio has drawn mixed reactions from analysts.